+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Malaria Diagnostics Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5805772
The global malaria diagnostics market value was USD 769.5 million in 2022, driven by the increasing incidence of malaria cases across the globe. The market size is anticipated to grow at a CAGR of 5.5% during the forecast period of 2023-2031 to achieve a value of USD 1,242.4 million by 2031.

Malaria Diagnostics: Introduction

Malaria is a life-threatening infectious disease caused by the Plasmodium parasite and transmitted through the bite of infected mosquitoes. It is a global health concern, particularly in regions with high malaria prevalence, such as sub-Saharan Africa, Southeast Asia, and Latin America. Early and accurate diagnosis is crucial for effective malaria management and treatment.

Malaria diagnostics play a vital role in identifying the presence of malaria parasites in patients and determining the species of the parasite, which helps in guiding appropriate treatment strategies. Over the years, significant advancements have been made in malaria diagnostic tools and technologies, leading to improved accuracy, speed, and accessibility of malaria testing.

Key Trends in the Malaria Diagnostics Market

Some key trends involved in the malaria diagnostics market are as follows:
  • Point-of-care Testing: There has been a growing trend towards the development and adoption of point-of-care diagnostic tests for malaria. These tests are portable, easy to use, and provide rapid results, enabling healthcare professionals to diagnose malaria quickly and initiate timely treatment. Rapid diagnostic tests (RDTs) based on immunochromatographic assays are widely used as point-of-care tests due to their simplicity, affordability, and reliability
  • Molecular Diagnostics: Molecular diagnostic techniques, such as polymerase chain reaction (PCR), have gained prominence in malaria diagnosis. PCR-based tests offer high sensitivity and specificity, allowing for accurate detection and quantification of malaria parasites. These techniques are particularly useful in detecting low-level parasitemia and differentiating between different species of Plasmodium
  • Technological Innovations: The malaria diagnostics market has witnessed significant technological advancements, including the development of innovative tools and devices. This includes the use of digital platforms, mobile applications, and remote monitoring systems to improve data collection, transmission, and analysis. These technologies enhance the efficiency of malaria surveillance, enable real-time reporting, and support public health interventions

Malaria Diagnostics Market Segmentations

Market Breakup by Technology

  • Microscopy
  • Rapid Diagnostic Tests

Molecular Diagnostic Tests

  • Conventional PCR
  • Real-Time PCR

Market Breakup by Treatment Channel

  • Public
  • Private

Market Breakup by End User

  • Hospitals
  • Clinics
  • Diagnostic Centres
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Malaria Diagnostics Market Scenario

The market for malaria diagnostics has witnessed significant growth and development in recent years. Malaria remains a major global health concern, particularly in regions with high malaria prevalence. The need for accurate and timely diagnosis is crucial for effective management and treatment of the disease.

The market for malaria diagnostics is driven by several factors. First and foremost, the increasing incidence of malaria cases worldwide has created a growing demand for reliable and efficient diagnostic tools. As malaria control and elimination programs are implemented, there is a greater focus on early detection and prompt treatment to reduce the burden of the disease.

Advancements in technology have played a pivotal role in the market growth. There has been a shift towards the development of rapid diagnostic tests (RDTs) that provide quick and accurate results at the point of care. These tests are easy to use, cost-effective, and do not require complex laboratory infrastructure, making them ideal for resource-limited settings.

In conclusion, the market for malaria diagnostics is witnessing significant growth driven by the increasing incidence of malaria, advancements in technology, and efforts to improve accessibility and affordability. With ongoing research and development, technological innovations, and collaborative initiatives, the market is expected to continue expanding, playing a vital role in the global fight against malaria.

Malaria Diagnostics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • ACCESS BIO. INC
  • Abbott
  • BioMérieux SA
  • Ortho Clinical Diagnostics
  • Thermo Fisher Scientific
  • PREMIER MEDICAL CORPORATION PVT LTD
  • Siemens, Bio-Rad Laboratories, Inc
  • Hemex Health
  • QuantuMDx Group Ltd
  • Meridian Bioscience Europe B.V
  • Intellectual Ventures Management LLC
  • Novartis AG
  • BD
  • FYODOR BIOTECHNOLOGIES
  • Drucker Diagnostics
  • Danaher
  • Beckman Coulter, Inc.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Malaria Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Malaria Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Malaria Epidemiology (2016-2031)
5.3 Europe Malaria Epidemiology (2016-2031)
5.4 Asia Pacific Malaria Epidemiology (2016-2031)
5.5 Latin America Malaria Epidemiology (2016-2031)
5.6 Middle East and Africa Malaria Epidemiology (2016-2031)
6 Global Malaria Diagnostics Market Overview
6.1 Global Malaria Diagnostics Market Historical Value (2016-2022)
6.2 Global Malaria Diagnostics Market Forecast Value (2023-2031)
7 Global Malaria Diagnostics Market Landscape
7.1 Global Malaria Diagnostics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Malaria Diagnostics: Product Landscape
7.2.1 Analysis by Technology
7.2.2 Analysis by End User
7.2.3 Analysis by Region
8 Malaria Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Global Malaria Diagnostics Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Global Malaria Diagnostics Market Segmentation
10.1 Global Malaria Diagnostics Market by Technology
10.1.1 Market Overview
10.1.2 Microscopy
10.1.3 Rapid Diagnostic Tests
10.1.4 Molecular Diagnostic Tests
10.1.4.1 Conventional PCR
10.1.4.2 Real-Time PCR
10.2 Global Malaria Diagnostics Market by Treatment Channel
10.2.1 Market Overview
10.2.2 Public
10.2.3 Private
10.3 Global Malaria Diagnostics Market by End User
10.3.1 Market Overview
10.3.2 Hospitals
10.3.3 Clinics
10.3.4 Diagnostic Centres
10.3.5 Others
10.4 Global Malaria Diagnostics Market by Region
10.4.1 Market Overview
10.4.2 North America
10.4.3 Europe
10.4.4 Asia Pacific
10.4.5 Latin America
10.4.6 Middle East and Africa
11 North America Malaria Diagnostics Market
11.1 Market Share by Country
11.2 United States of America
11.3 Canada
12 Europe Malaria Diagnostics Market
12.1 Market Share by Country
12.2 United Kingdom
12.3 Germany
12.4 France
12.5 Italy
12.6 Others
13 Asia Pacific Malaria Diagnostics Market
13.1 Market Share by Country
13.2 China
13.3 Japan
13.4 India
13.5 ASEAN
13.6 Australia
13.7 Others
14 Latin America Malaria Diagnostics Market
14.1 Market Share by Country
14.2 Brazil
14.3 Argentina
14.4 Mexico
14.5 Others
15 Middle East and Africa Malaria Diagnostics Market
15.1 Market Share by Country
15.2 Saudi Arabia
15.3 United Arab Emirates
15.4 Nigeria
15.5 South Africa
15.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 ACCESS BIO. INC
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Abbott
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 BioMérieux SA
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Ortho Clinical Diagnostics
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Thermo Fisher Scientific
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 PREMIER MEDICAL CORPORATION PVT LTD.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Siemens, Bio-Rad Laboratories, Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Hemex Health
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 QuantuMDx Group Ltd.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Meridian Bioscience Europe B.V.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Intellectual Ventures Management LLC.
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Novartis AG
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 BD
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 FYODOR BIOTECHNOLOGIES
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
22.15 Drucker Diagnostics
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisitions
22.15.5 Certifications
22.16 Danaher
22.16.1 Financial Analysis
22.16.2 Product Portfolio
22.16.3 Demographic Reach and Achievements
22.16.4 Mergers and Acquisitions
22.16.5 Certifications
22.17 Beckman Coulter, Inc.
22.17.1 Financial Analysis
22.17.2 Product Portfolio
22.17.3 Demographic Reach and Achievements
22.17.4 Mergers and Acquisitions
22.17.5 Certifications
23 Malaria Diagnostics Market- Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket

Companies Mentioned

  • ACCESS BIO. INC
  • Abbott
  • BioMérieux SA
  • Ortho Clinical Diagnostics
  • Thermo Fisher Scientific
  • PREMIER MEDICAL CORPORATION PVT LTD.
  • Siemens
  • Bio-Rad Laboratories Inc.
  • Hemex Health
  • QuantuMDx Group Ltd.
  • Meridian Bioscience Europe B.V.
  • Intellectual Ventures Management LLC.
  • Novartis AG
  • BD
  • FYODOR BIOTECHNOLOGIES
  • Drucker Diagnostics
  • Danaher
  • Beckman Coulter Inc.

Methodology

Loading
LOADING...

Table Information